STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
276: Who discovered GLP-1? Plus: BrainStorm at the FDA and biotech's slump
Our colleague Elaine Chen joins us to explain the story of Svetlana Mojsov, a chemist who played a vital role in the discovery of GLP-1 who has spent decades fighting for proper recognition. We also discuss the latest news in the life sciences, including the FDA hearing on a BrainStorm Cell Therapeutics' polarizing ALS treatment, the end of the road for a once-vaunted drug developer, and the sorry state of biotech stocks.
275: A thorny ALS debate at the FDA, and the promise of artificial wombs
Our colleague Lizzy Lawrence joins us to explain the promise of artificial wombs and the debate over how to ethically develop them. We also discuss a momentous upcoming meeting in which FDA will consider the thorny case of a potential medicine for ALS whose supporting evidence has polarized patients and physicians.
274: Covid’s latest surge, Alnylam at the FDA, & the end of an era
Our colleague Helen Branswell joins us to discuss the state of the Covid-19 pandemic heading into the fall and the rollout of boosters shots aimed at the latest viral variants. We also discuss the latest news in the life sciences, including an IPO implosion, a debate at the FDA, and the ups and downs of a career in biotech.
273: Back to school for biotech, Biogen's potential pivot, & Illumina's next chapter
Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters the busy back third of 2023. We also discuss the latest news in the life sciences, including some scientific evolution at Biogen, new leadership at Illumina, and the future of CRISPR medicine.
272: Vivek's star turn, leaky drug data, & biotech as family business
We discuss how Vivek Ramaswamy, fresh off his headline-grabbing debut at the first Republican presidential debate, went from a drug industry entrepreneur to a GOP rising star — and how his former biotech colleagues are reacting to it. We also explain the latest news in the life sciences, including a curious data leak and the family business of a famed biotech inventor.
271: Racing for gene therapy, a pioneering approval, & startups in the lurch
Our colleague Jason Mast joins us to explain how the approval of a landmark gene therapy for Duchenne muscular dystrophy set in motion a frantic race to get children treated before their 6th birthdays. Then, HSBC Managing Director Jonathan Norris calls in to discuss why so many biotech startups are facing financial bridges to nowhere.
Good podcast but that theme song
Great content, smart hosts but that theme song/intro is jarring and amateurish.
Absolutely thrilled about this phenomenal podcast centered on pharma and biotech news! Weekly episodes are fantastic, though I’d be over the moon if they could dive even deeper and extend the show’s length. Keep up the awesome work! Welcome back, Allison (DeAngelis)!
Great podcast! Focus on news and not sales pitch like interviews such as that recent Novovax piece. Keep up the good work!